107 related articles for article (PubMed ID: 27179127)
1. Metabolism and Disposition of the Hepatitis C Protease Inhibitor Paritaprevir in Humans.
Shen J; Serby M; Reed A; Lee AJ; Zhang X; Marsh K; Khatri A; Menon R; Kavetskaia O; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1164-73. PubMed ID: 27179127
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans.
Shen J; Serby M; Surber B; Lee AJ; Ma J; Badri P; Menon R; Kavetskaia O; de Morais SM; Sydor J; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1148-57. PubMed ID: 27179128
[TBL] [Abstract][Full Text] [Related]
3. Metabolism and Disposition of Hepatitis C Polymerase Inhibitor Dasabuvir in Humans.
Shen J; Serby M; Reed A; Lee AJ; Menon R; Zhang X; Marsh K; Wan X; Kavetskaia O; Fischer V
Drug Metab Dispos; 2016 Aug; 44(8):1139-47. PubMed ID: 27179126
[TBL] [Abstract][Full Text] [Related]
4. Dose- and Formulation-Dependent Non-Linear Pharmacokinetic Model of Paritaprevir, a Protease Inhibitor for the Treatment of Hepatitis C Virus Infection: Combined Analysis from 12 Phase I Studies.
Polepally AR; Mensing S; Khatri A; Beck D; Liu W; Awni WM; Menon RM; Dutta S
Clin Pharmacokinet; 2016 Sep; 55(9):1091-101. PubMed ID: 27000758
[TBL] [Abstract][Full Text] [Related]
5. Clinical Pharmacokinetics of Paritaprevir.
Menon RM; Polepally AR; Khatri A; Awni WM; Dutta S
Clin Pharmacokinet; 2017 Oct; 56(10):1125-1137. PubMed ID: 28236252
[TBL] [Abstract][Full Text] [Related]
6. Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
de Bruijne J; van Vliet A; Weegink CJ; Mazur W; Wiercinska-Drapało A; Simon K; Cholewińska-Szymańska G; Kapocsi J; Várkonyi I; Zhou XJ; Temam MF; Molles J; Chen J; Pietropaolo K; McCarville JF; Sullivan-Bólyai JZ; Mayers D; Reesink H
Antivir Ther; 2012; 17(4):633-42. PubMed ID: 22427481
[TBL] [Abstract][Full Text] [Related]
7. The metabolism and disposition of a potent inhibitor of hepatitis C virus NS3/4A protease.
Monteagudo E; Fonsi M; Chu X; Bleasby K; Evers R; Pucci V; Orsale MV; Cianetti S; Ferrara M; Harper S; Laufer R; Rowley M; Summa V
Xenobiotica; 2010 Dec; 40(12):826-39. PubMed ID: 20925584
[TBL] [Abstract][Full Text] [Related]
8. Effects of omeprazole and ritonavir on absorption and elimination of the hepatitis C virus NS5A inhibitor GSK2336805 in healthy adults.
Adkison KK; Jones LS; Lou Y; Gan J; Wilfret DA
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):338-45. PubMed ID: 27129005
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluations of P4-benzoxaborole-substituted macrocyclic inhibitors of HCV NS3 protease.
Ding CZ; Zhang YK; Li X; Liu Y; Zhang S; Zhou Y; Plattner JJ; Baker SJ; Liu L; Duan M; Jarvest RL; Ji J; Kazmierski WM; Tallant MD; Wright LL; Smith GK; Crosby RM; Wang AA; Ni ZJ; Zou W; Wright J
Bioorg Med Chem Lett; 2010 Dec; 20(24):7317-22. PubMed ID: 21067923
[TBL] [Abstract][Full Text] [Related]
10. The discovery and optimization of naphthalene-linked P2-P4 Macrocycles as inhibitors of HCV NS3 protease.
Bowsher M; Hiebert S; Li R; Wang AX; Friborg J; Yu F; Hernandez D; Wang YK; Klei H; Rajamani R; Mosure K; Knipe JO; Meanwell NA; McPhee F; Scola PM
Bioorg Med Chem Lett; 2018 Jan; 28(1):43-48. PubMed ID: 29162454
[TBL] [Abstract][Full Text] [Related]
11. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics.
Lawitz E; Sulkowski M; Jacobson I; Kraft WK; Maliakkal B; Al-Ibrahim M; Gordon SC; Kwo P; Rockstroh JK; Panorchan P; Miller M; Caro L; Barnard R; Hwang PM; Gress J; Quirk E; Mobashery N
Antiviral Res; 2013 Sep; 99(3):214-20. PubMed ID: 23747481
[TBL] [Abstract][Full Text] [Related]
12. Macrocyclic Hepatitis C Virus NS3/4A Protease Inhibitors: An Overview of Medicinal Chemistry.
Pillaiyar T; Namasivayam V; Manickam M
Curr Med Chem; 2016; 23(29):3404-3447. PubMed ID: 27160539
[TBL] [Abstract][Full Text] [Related]
13. Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Badri PS; Dutta S; Wang H; Podsadecki TJ; Polepally AR; Khatri A; Zha J; Chiu YL; Awni WM; Menon RM
Antimicrob Agents Chemother; 2016 Jan; 60(1):105-14. PubMed ID: 26459906
[TBL] [Abstract][Full Text] [Related]
14. Ultra-rapid cardiotoxicity of the hepatitis C virus protease inhibitor BILN 2061 in the urokinase-type plasminogen activator mouse.
Vanwolleghem T; Meuleman P; Libbrecht L; Roskams T; De Vos R; Leroux-Roels G
Gastroenterology; 2007 Oct; 133(4):1144-55. PubMed ID: 17919490
[TBL] [Abstract][Full Text] [Related]
15. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
[TBL] [Abstract][Full Text] [Related]
16. Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED.
Bu G; Danelius E; Wieske LHE; Gonen T
Adv Biol (Weinh); 2024 May; 8(5):e2300570. PubMed ID: 38381052
[TBL] [Abstract][Full Text] [Related]
17. GP205, a new hepatitis C virus NS3/4A protease inhibitor, displays higher metabolic stability in vitro and drug exposure in vivo.
Zhai PB; Qing J; Li B; Zhang LQ; Ma L; Chen L
Acta Pharmacol Sin; 2018 Nov; 39(11):1746-1752. PubMed ID: 29930277
[TBL] [Abstract][Full Text] [Related]
18. A randomized, double blind, dose escalation, first time in human study to assess the safety, tolerability, pharmacokinetics, and antiviral activity of single doses of GSK2485852 in chronically infected hepatitis C subjects.
Wilfret DA; Walker J; Voitenleitner C; Baptiste-Brown S; Lovern M; Kim J; Adkison K; Shotwell B; Mathis A; Moss L; Lee D; Yu L; Gan J; Spaltenstein A
Clin Pharmacol Drug Dev; 2014 Nov; 3(6):439-48. PubMed ID: 27129119
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Gane EJ; Schwabe C; Hyland RH; Yang Y; Svarovskaia E; Stamm LM; Brainard DM; McHutchison JG; Stedman CA
Gastroenterology; 2016 Sep; 151(3):448-456.e1. PubMed ID: 27240903
[TBL] [Abstract][Full Text] [Related]
20. Understanding of the drug resistance mechanism of hepatitis C virus NS3/4A to paritaprevir due to D168N/Y mutations: A molecular dynamics simulation perspective.
Boonma T; Nutho B; Rungrotmongkol T; Nunthaboot N
Comput Biol Chem; 2019 Dec; 83():107154. PubMed ID: 31751885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
